

## Application No.: 08/765,695

Docket No.: HO-P01525US0

- 1. Canceled
- 2. Canceled
- 3. Canceled
- 4. Canceled
- 5. Canceled
- 6. Canceled
- 7. Canceled
- 8. Canceled
- 9. Canceled
- 10. Canceled
- 11. Canceled
- 12. Canceled
- 13. Canceled
- 14. Canceled
- 15. Canceled
- 16. Canceled
- 17. Canceled
- 18. Canceled
- 19. Canceled
- 20. Canceled
- 21. Canceled



## Application No.: 08/765,695

Docket No.: HO-P01525US0

- 22. Canceled
- 23. Canceled
- 24. Canceled
- 25. Canceled
- 26. Canceled
- 27. Canceled
- 28. Canceled
- 29. Canceled
- 30. Canceled
- 31. Canceled
- 32. Canceled
- 33. Canceled
- 34. Canceled
- 35. Canceled



Application No.: 08/765,695 Docket No.: HO-P01525US0

36. (currently amended) A method for the treatment of a disease condition in a mammal, which condition means the presence of specific cells that are associated with the condition by the expression of a disease specific cell surface structure, wherein one administers to the mammal a therapeutically effective amount of covalent conjugate that is able to activate T lymphocytes to lyse cells that carry the disease specific cell surface structure and comprises:

a. a biospecific affinity counterpart that is capable of binding to said surface structure, and

## b. a peptide that

- i. contains an amino acid sequence that is derived from a superantigen selected from the group consisting of staphylococcal enterotoxin A, B, C1, C2, D and E,
- ii. has the ability to bind to a VB of a T cell receptor, and
- iii. has been mutated in that at least one of the following amino acid residue substitutions have been made: F47A, N128A, H187A, H225A or D227A in staphylococcal enterotoxin A or corresponding residues in the other superantigens to show a modified ability to bind to MHC class II antigens compared to the superantigens from which the peptide is derived.
- 37. Canceled
- 38. Canceled
- 39. Canceled
- 40. Canceled
- 41. Canceled
- 42. Canceled
- 43. Canceled
- 44. Canceled
- 45. Canceled



Application No.: 08/765,695 Docket No.: HO-P01525US0

- 46. Canceled
- 47. Canceled
- 48. Canceled
- 49. Canceled
- 50. Canceled
- 51. Canceled
- 52. Canceled
- 53. Withdrawn
- 54. Withdrawn
- 55. Withdrawn
- 56. Withdrawn
- 57. Withdrawn
- 58. (new) The method of claim 36, wherein the disease is selected from the group consisting of cancer, viral infection, autoimmune disease and parasitic infestation.
- 59. (new) The method of claim 58, wherein the disease is cancer.
- 60. (new) The method of claim 36, wherein the biospecific affinity counterpart comprises polypeptide structure.
- 61. (new) The method of claim 60, wherein the biospecific affinity counterpart is selected from the group consisting of an antibody or an antigen-binding fragment thereof.
- 62. (new) The method of claim 60, wherein the biospecific counterpart and the peptide are fused together.
- 63. (new) The method of claim 61, wherein the biospecific counterpart and the peptide are fused together.
- 64. (new) The method of claim 36, wherein the superantigen is staphylococcal enterotoxin A.